Study:
Phase II to Treat Multiple Myeloma Patients With Cytoxan and Vincristine After Cycling Myeloma Cells With rHuGM-CSF
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. GM-CSF may make cancer cells more sensitive to the effects of
chemotherapy. Combining more than one drug with GM-CSF may kill more tumor cells.
Purpose:
Phase II trial to study the effectiveness of combination chemotherapy, consisting of
cyclophosphamide plus vincristine, following GM-CSF in treating patients with multiple
myeloma that has not responded to previous treatment.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Multiple Myeloma and Plasma Cell Neoplasm |
Biological: sargramostim
Drug: cyclophosphamide
Drug: prednisone
Drug: vincristine sulfate |
Phase 2 |
Verified by
The Cleveland Clinic
March, 2001
Sponsored by: The Cleveland Clinic
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00003490
Study Type: Interventional
Study Design: Treatment
Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States
Mohamad A. Hussein, MD., Study Chair